CD308 FLT1 (fms-related tyrosine kinase 1), VEGFR1 (vascular epithelial growth factor receptor 1)
Molecule TypeAntigen ExpressionMolecular Weight
Min / Max
Non-lineage Restricted Molecule
Type 1 glycoprotein
Lung
Placenta
Kidney
Brain
Heart
Monocyte
Endothelium
Liver
Trophoblast
Peripheral blood
Osteoblast
152 / 152

Expression

CD308 is expressed mostly in normal lung, placenta, liver, kidney, heart and brain tissues.  Expression is specifically expressed in most vascular endothelium cells, peripheral blood monocytes, osteoblasts and trophoblasts.  There is no expression in tumor cell lines.



Structure

MOLECULAR FAMILY NAME: Belongs to the tyrosine protein kinase receptor family.

CD308 is a single-pass type-1 1312 aa glycoprotein.  It contains a 26 aa signal sequence, a 732 aa extracellular domain which contains 7 Ig-like C2-type domains and 13 potential N-linked glycosylation sites in the ectodomain, a transmembrane domain and an intracellular 332 aa cytoplasmic domain which contains a kinase insert sequence and 6 phosphotyrosines.  CD308 together with CD309 and CD310 constitute the flt subfamily of receptors.  CD308 is a member of type-3 kinase receptors.

MOLECULAR MASS

POST-TRANSCRIPTIONAL MODIFICATION

Alternative splicing yields 2 different isoforms, a membrane bound form and a soluble form.

POST-TRANSLATIONAL MODIFICATION

CD308 has 13 N-linked glycosylation sites.



Ligands
LIGANDS AND MOLECULE ASSOCIATED WITH CD308

CD308 binds vascular endothelial growth factor (VEGF) and placenta growth factor (PIGF).

Function
CD308 is an important mediator of stem cell recruitment and mobilization, angiogenesis and inflammation.  CD308 has a tyrosine-kinase activity which is important for the control of cell proliferation and differentiation and plays a role in vascular development and regulation of vascular permeability. 

BIOCHEMICAL ACTIVITY: No information.

DISEASE RELEVANCE AND FUNCTION OF CD308 IN INTACT ANIMAL

CD308 is a potential target in the treatment of inflammation and atherosclerotic plaque growth.  The placental growth factor used CD308 to stimulate angiogenesis and collateral vessel development to bypass atherosclerotic lesions causing ischemia.  The anti-CD308 mAb can suppress angiogenesis in tumors and ischemic retinas, in atherosclerotic plaque formation, in inflammation and joint destruction associated with autoimmune arthritis and to reduce mobilization of bone-marrow derived stem cells into peripheral blood and infiltration of CD308 expressing leukocytes into tissues.  Ligation of CD308 induces chemotactic migration of mesenchymal progenitor cells and stimulation of  osteoblast proliferation suggests CD308 is important in bone formation and remodeling.



Comments
MOLECULAR INTERACTIONS-
PROTEINS AND DNA ELEMENTS WHICH REGULATE TRANSCRIPTION OF CD308: No information.

SUBSTRATES: No information.

ENZYMES WHICH MODIFY CD308: No information.

Database accession numbers
AnimalPIRSWISSPROTEMGBL/GENBANK
 
HumanEntrezgene 2321P17948
Antibodies

Revised June 25, 2008


Contact us: Webmaster |  509-335-9515 | Accessibility | Copyright | Policies
College of Veterinary Medicine Washington State University, Pullman, WA, 99164-7010 USA
Copyright 1995-2003 Washington State University